Cargando…
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa
BACKGROUND: We investigated safety, tolerability, and immunogenicity of the heterologous 2-dose Ebola vaccination regimen in healthy and HIV-infected adults with different intervals between Ebola vaccinations. METHODS AND FINDINGS: In this randomised, observer-blind, placebo-controlled Phase II tria...
Autores principales: | Barry, Houreratou, Mutua, Gaudensia, Kibuuka, Hannah, Anywaine, Zacchaeus, Sirima, Sodiomon B., Meda, Nicolas, Anzala, Omu, Eholie, Serge, Bétard, Christine, Richert, Laura, Lacabaratz, Christine, McElrath, M. Juliana, De Rosa, Stephen, Cohen, Kristen W., Shukarev, Georgi, Robinson, Cynthia, Gaddah, Auguste, Heerwegh, Dirk, Bockstal, Viki, Luhn, Kerstin, Leyssen, Maarten, Douoguih, Macaya, Thiébaut, Rodolphe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8555783/ https://www.ncbi.nlm.nih.gov/pubmed/34714820 http://dx.doi.org/10.1371/journal.pmed.1003813 |
Ejemplares similares
-
Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial
por: Anywaine, Zacchaeus, et al.
Publicado: (2022) -
Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya
por: Mutua, Gaudensia, et al.
Publicado: (2019) -
Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen
por: Bockstal, Viki, et al.
Publicado: (2021) -
NK Cell Subset Redistribution and Antibody Dependent Activation after Ebola Vaccination in Africans
por: Wagstaffe, Helen R., et al.
Publicado: (2022) -
Non-human primate to human immunobridging demonstrates a protective effect of Ad26.ZEBOV, MVA-BN-Filo vaccine against Ebola
por: Bockstal, Viki, et al.
Publicado: (2022)